Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,820.00+3.99%ETH$2,441.28+6.67%GOLD$4,072.20+3.34%OIL$88.04-8.38%
Smart Investors Daily
SID Premium
GN

NASDAQ · GNPX

Genprex, Inc.

Healthcare · Biotechnology

$2.31

Down-$0.17 (-7.36%)

Updated Nov 4, 2026, 10:39 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.29M
P/E ratio
-0.15
Dividend yield
0.00%
52-week range
$0.42 – $12.61
Volume
145.22K
Avg. volume
716.01K

Price performance · GNPX

GNPX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

GNPX closed at $2.31 after 21 trading sessions, down 11.49% for the selected period.

Last close
$2.31
Period change
-11.49%
Period low
$1.81
Period high
$2.75
Daily close
View OHLC price history
GNPX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$2.24$2.38$2.24$2.31145.22K
Nov 2, 2026$2.33$2.3677$2.159$2.23243.42K
Oct 30, 2026$2.04$2.27$2.02$2.24184.02K
Oct 29, 2026$1.86$2.10$1.86$2.04155.27K
Oct 28, 2026$1.94$2.05$1.8344$2.01110.61K
Oct 27, 2026$1.86$1.9646$1.71$1.95112.56K
Oct 26, 2026$1.86$1.8738$1.7907$1.8176.52K
Oct 23, 2026$2.08$2.08$1.79$1.81215.2K
Oct 22, 2026$1.99$2.05$1.98$1.9894.93K
Oct 21, 2026$2.20$2.20$1.9101$2.05362.92K
Oct 20, 2026$2.07$2.18$2.03$2.13234.3K
Oct 19, 2026$2.15$2.215$2.06$2.06246.4K
Oct 16, 2026$2.27$2.32$2.10$2.11127.91K
Oct 15, 2026$2.30$2.43$2.2149$2.29225.95K
Oct 14, 2026$2.50$2.55$2.30$2.33281.62K
Oct 13, 2026$2.65$2.6916$2.51$2.51171K
Oct 12, 2026$2.88$2.88$2.57$2.69283.45K
Oct 9, 2026$2.81$2.93$2.64$2.72202.27K
Oct 8, 2026$2.69$2.81$2.659$2.75252.43K
Oct 7, 2026$2.62$2.78$2.58$2.62227.57K
Oct 6, 2026$2.74$2.75$2.58$2.61165.26K

Latest GNPX news

The latest Smart Investors Daily articles mentioning GNPX.

Stock researchCompany · Overview

GNPX research

Overview

Company profile and research snapshot.

Company profile

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.65
Implied upside
—
Analysts
7
GNPX recent ratings
DateFirmRatingTarget
May 17, 2024HC Wainwright & Co.Buy—
May 15, 2024HC Wainwright & Co.Buy—
Apr 4, 2024HC Wainwright & Co.Buy—
Apr 3, 2024HC Wainwright & Co.Buy—
Mar 25, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today announced that research conducted under its sponsored research collaboration with Meharry Medical College in Nashville, Tennessee will be featured at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting, taking place November 4-7, 2026, in National

Yahoo · Oct 21, 2026

Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes, today highlighted new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular processes associated with healthy brain aging and supporting broader understanding of how disruption of normal biological function ma

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By